The target, which includes new indications and line extensions for existing products as well as new molecular entities (NMEs), follows a total of 11 launches, including six NMEs, by the subsidiary in the fiscal year ended 30 November.
written on 11.03.2014
Pfizer looks to maintain innovation lead in Japan
